Brief: Eurocine Vaccines Enters Into Research And Collaboration Agreement With Spixia Biotechnology
Aug 21 (Reuters) - Eurocine Vaccines AB EUCI.TE :
* SAID ON THURSDAY ENTERED INTO AGREEMENT WITH SPIXIA
BIOTECHNOLOGY ON DEVELOPMENT AND COMMERCIALIZATION OF CHLAMYDIA
VACCINE
Source text for Eikon: urn:newsml:reuters.com:*:nWkr7cnBcc
Further company coverage: EUCI.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Nidhogg Resources Holding AB (publ)
See all newsBrief: Nidhogg Resources Holding Resolves On A Directed Set-Off Share Issue
Brief: Nidhogg Resources Holding AB Announces The Termination Of The Al Baraka Project In Egypt
Brief: Eurocine Vaccines Q4 EPS at SEK -0.111
Brief: Eurocine Vaccines Says Decides To Develop mRNA-Based Vaccine Candidate Against Chlamydia
Brief: Eurocine Vaccines Expands Its Portfolio With A Therapeutic Hsv-2 Vaccine Candidate